NQMC Update Service: July 10, 2017 | NHS Scotland - Scottish Intercollegiate Guidelines Network (SIGN)

NQMC Update Service: July 10, 2017

NHS Scotland

• Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing clinical examination of relevant draining lymph node basins as part of clinical staging.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing diagnostic excision biopsy who undergo a wide local excision.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing groin block dissection who have been referred to a lymphoedema service.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing partial biopsy who undergo a wide local excision.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their diagnostic excision biopsy.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their partial biopsy.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma who have their diagnostic excision biopsy carried out by a skin cancer clinician.
• Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo diagnostic excision biopsy where the surgical pathology report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).
• Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo sentinel node biopsy (SNB) where the SNB report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).
• Cutaneous melanoma: proportion of patients with stage III and IV cutaneous melanoma who undergo CT or positron emission tomography (PET) CT prior to completion lymphadenectomy.
• Cutaneous melanoma: proportion of patients with unresectable stage III and IV cutaneous melanoma who undergo systemic anti-cancer therapy (SACT).
• Cutaneous melanoma: proportion of patients with unresectable stage III or IV cutaneous melanoma who have their BRAF status checked.
• Lung cancer: proportion of patients with a pathological diagnosis of non small cell lung cancer (NSCLC) who have a tumour subtype identified.
• Lung cancer: proportion of patients with a pathological diagnosis of stage IIIB or IV non small cell lung cancer (NSCLC) who have molecular profiling undertaken.
• Lung cancer: proportion of patients with limited stage (stage I to IIIB) small cell lung cancer (SCLC), performance status 0 or 1, who receive chemoradiotherapy (radiotherapy greater than or equal to 40Gy and concurrent or sequential platinum-based chemotherapy).
• Lung cancer: proportion of patients with lung cancer not undergoing surgery who receive radiotherapy (greater than or equal to 54Gy) ± chemotherapy, or stereotactic ablative radiotherapy (SABR).
• Lung cancer: proportion of patients with lung cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
• Lung cancer: proportion of patients with lung cancer who are enrolled in an interventional clinical trial or translational research.
• Lung cancer: proportion of patients with lung cancer who have a pathological diagnosis (including following surgical resection).
• Lung cancer: proportion of patients with lung cancer who receive active treatment who die within 30 days of treatment.
• Lung cancer: proportion of patients with lung cancer who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who have a cytological/histological diagnosis prior to treatment.
• Lung cancer: proportion of patients with lung cancer who receive treatment with curative intent (surgery, radical radiotherapy or chemoradiotherapy) who die within 90 days of treatment.
• Lung cancer: proportion of patients with N2 disease who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo contrast enhanced CT or contrast enhanced MRI prior to start of treatment.
• Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) not undergoing surgery who receive systemic anti-cancer therapy.
• Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) undergoing resection by lobectomy or pneumonectomy who have at least 1 node from at least 3 N2 stations sampled at time of resection or at previous mediastinoscopy.
• Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo PET CT prior to start of treatment.
• Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who undergo surgical resection.
• Lung cancer: proportion of patients with small cell lung cancer (SCLC) not undergoing treatment with curative intent who receive palliative chemotherapy.
• Lung cancer: proportion of patients with small cell lung cancer (SCLC) who receive chemotherapy ± radiotherapy.
• Lung cancer: proportion of patients with stage I lung cancer not undergoing surgery who receive stereotactic ablative radiotherapy (SABR).
• Lung cancer: proportion of patients with stage I to II (T1aN0 to T2bN1, or T3N0) non small cell lung cancer (NSCLC) who undergo surgical resection.
• Lung cancer: proportion of patients with stage IIIA non small cell lung cancer (NSCLC), with performance status 0-1, not undergoing surgery who receive chemoradiotherapy (radiotherapy greater than or equal to 54Gy and concurrent or sequential chemotherapy).
• Lung cancer: proportion of patients with stage IIIB or IV non small cell lung cancer (NSCLC), with performance status 0 to 2 not undergoing surgery that are epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive who receive biological therapy.
• Lymphoma: proportion of patients with Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL) undergoing treatment with curative intent who have MYC testing prior to treatment.
• Lymphoma: proportion of patients with classical Hodgkin lymphoma (CHL) undergoing treatment with curative intent who undergo PET CT prior to treatment and within 2 weeks of radiology request.
• Lymphoma: proportion of patients with classical Hodgkin lymphoma (CHL) undergoing treatment with curative intent who undergo PET CT prior to treatment.
• Lymphoma: proportion of patients with diffuse large B cell lymphoma (DLBCL) who are undergoing chemotherapy treatment with curative intent who undergo CT of chest, abdomen and pelvis or PET CT at end of chemotherapy treatment.
• Lymphoma: proportion of patients with early stage (stage 1a or 2a) classical Hodgkin lymphoma (CHL) who receive combined modality treatment (chemotherapy and radiotherapy).
• Lymphoma: proportion of patients with follicular lymphoma and diffuse large B cell lymphoma (DLBCL) who receive chemotherapy in combination with rituximab.
• Lymphoma: proportion of patients with grade 3b follicular lymphoma who receive treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy.
• Lymphoma: proportion of patients with lymphoma undergoing rituximab based treatment who have hepatitis B, hepatitis C and HIV status checked prior to treatment.
• Lymphoma: proportion of patients with lymphoma undergoing treatment with curative intent who undergo CT of chest, abdomen and pelvis or PET CT scanning prior to treatment and within 2 weeks of radiology request.
• Lymphoma: proportion of patients with lymphoma undergoing treatment with curative intent who undergo CT of chest, abdomen and pelvis or PET CT scanning prior to treatment.
• Lymphoma: proportion of patients with lymphoma who are discussed at a multidisciplinary team (MDT) meeting within 6 weeks of diagnosis.
• Lymphoma: proportion of patients with nodal, non-bulky stage 1a diffuse large B-cell lymphoma (DLBCL) who receive local radiotherapy, in combination with chemotherapy.
• Lymphoma: proportion of patients with primary cutaneous lymphoma who are discussed at a specialist multidisciplinary team (MDT) meeting.